Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals signed a licensing agreement with Shanghai JMT-Bio Technology, a unit of CSPC Pharmaceutical Group (HKG:1093), to develop, sell, and commercialize tumor-related drug JSKN003 in mainland China, according to a Sunday filing with the Hong Kong bourse.
JMT-Bio will obtain the exclusive license and sublicense rights to develop, sell, offer, and commercialize JSKN003 and will be the sole authorized marketer holder. JMT-Bio will bear further clinical development expenses for the drug. Alphamab will have the right to supply the drug outside JMT-Bio's territory, including Hong Kong, Taiwan, and Macau.
Alphamab will be entitled to 3.08 billion yuan, including 400 million yuan and 300 million in upfront and sales milestone payments. The company will also receive royalties on medication sales.
The pharmaceutical stocks were up nearly 39% in recent trading, while CSPC Pharma's shares rose over 5%.
Price (HKD): $4.24, Change: $+1.2, Percent Change: +38.56%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。